Triple agonism is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers.
Second pass at: Triple agonism: additive, synergistic, or neither? — that is the question, and I have not found it answered plainly anywhere I have looked.
Posting a small dataset on Triple agonism. It is mine, it is uncontrolled, and the method is stated so it can be discounted appropriately.
What I would like is not agreement but a second dataset collected by someone with no stake in mine. If one exists I would rather read it than argue for this one.
Coming back to the opening post, because the follow-up matters more than the original answer.
One more thing on Triple agonism that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you notice that, the apparent contradiction disappears.
Picking up the opening post: that is the part I would want checked first.
Retatrutide is investigational. Anything obtained outside a trial is by definition research-use-only material with no human-use authorisation. This site will state that plainly rather than winking at it.
Anyone who has looked at this more carefully, please correct the record.
Triple agonism is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers.
Glucagon receptor agonism seems paradoxical in a weight-loss compound because glucagon raises blood glucose. The paradox resolves because glucagon agonism also increases energy expenditure and promotes hepatic fat oxidation, and the incretin components offset the glycaemic effect. In diabetes trials, HbA1c improved rather than worsened.
This follows post #4 rather than contradicting it.
Summarising the Triple agonism thread so far, since it is long and the answer is buried: the first reply has the method, the fourth has the correction to it, and the rest is people agreeing at length.
Worth separating two things that post #6 runs together.
Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others.
Take the reasoning and check the arithmetic; I do not always get it right.
Narrowing post #8, because the general version has more than one answer.
Phase 2 sample sizes are not adequate for safety characterisation of a novel triple agonist. Phase 3 is where that question gets answered. Using phase 2 results to make claims about safety profile is using the trial for a purpose it was not designed for.
That is what I would do. It may not be what is correct.
The version of Triple agonism that circulates here is a simplification of a simplification. It is not wrong, but it has lost the conditions under which it holds, and those conditions are where the interesting cases live.
Whether triple agonism is additive or synergistic is an open question and the published work does not answer it. A phase 2 trial without a dual-agonist comparator arm cannot distinguish the two.
That is what the documentation says. What happens in practice is usually close.
Post #9 is right about the mechanism and I think understates the practical bit.
Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.
Triple agonism was covered in the wiki last year and the page has a review date on it, which is a better starting point than my memory of a thread.
Filing a mild objection to the consensus on Triple agonism. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit.
Retatrutide is investigational. Anything obtained outside a trial is by definition research-use-only material with no human-use authorisation. This site will state that plainly rather than winking at it.
I would be glad to be shown a cleaner way of putting this.
Post #14 and I disagree about the size of the effect, not about the direction.
Triple agonism: is the effect additive, synergistic, or neither? A phase 2 comparison of tirzepatide (dual) to retatrutide (triple) would answer that question. The published data does not include such a direct comparison.
One caution on Triple agonism: everything above assumes the underlying documentation is what it claims to be. That assumption is doing real work and is rarely stated.
Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others.
The mechanism is plausible, which is not the same as established.
Reading back through the Triple agonism threads from last year, the same three questions come up every time and only one of them has ever been answered properly. That seems like a documentation gap rather than a knowledge gap.
Coming back to post #20, because the follow-up matters more than the original answer.
Triple agonism is well covered in the tag pages, and the older discussions are better than the recent ones because they were argued out properly. Worth twenty minutes before adding to this one.
This follows post #22 rather than contradicting it.
Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.
Marking my uncertainty on Triple agonism explicitly. I am confident about the direction, much less confident about the size, and not confident at all that it generalises past the case in the first post.
Hepatic effects: glucagon receptor agonism promotes hepatic fat oxidation, which is mechanistically plausible for benefit in metabolic liver disease. Whether that translates to improved clinical outcomes is being tested in phase 2 work.
The short answer was in the first line; everything after is the working.
Taking post #26 at face value and following it one step further.
Agreed on Triple agonism, with one qualification that I think matters. The reasoning holds for the case as described. Change the starting assumption and it does not, and the starting assumption is the part nobody states.
The question underneath Triple agonism is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it.
Write down what you would expect to see under each hypothesis before you collect anything. If they predict the same observation, collecting it will not help.